Evaluation of the Use of Submaximal Exercise Gas Exchange as a Clinical Marker in Pulmonary Arterial Hypertension.

Study ID
STU 052011-090

Cancer Related

Healthy Volunteers

Study Sites

  • Clements University Hospital

Danae Fields

Principal Investigator
Sonja Bartolome, M.D.


We will perform baseline submaximal exercise testing on 20 patients with Pulmonary arterial Hypertension (PaH) WHo Group 1 anD 20 patients with Pulmonary Venous Hypertension (PVH) WHo Group 2 either 1.) on initial diagnosis oR 2.) on follow-up clinic visits who have been treated sub-optimally with the intention of medication change or titration. These two groups of patient will be compared to 20 healthy age-matched volunteers.

The intention is to perform sub-maximal, symptom-limited exercise testing in all recruited subjects and to perform a repeat exercise test in the 40 patients (with PaH and PVH) six months after initiation or change in therapy.

The intention of the project will be to contrast the data provided by the SHaPe system in PaH WHo Group 1 patients, PVH WHo Group 2 (Pulmonary Venous Hypertension) and normal volunteers. We will compare this data with SF-36 quality of life scores, in addition to surrogate clinical markers of PH which are current standards of care (2D Transthoracic echocardiography and 6MWT, both to be completed at time of enrollment and again in 6 months). The purpose of this comparison will be to identify correlation of the SHaPe machine results with those of previously used clinical markers and to evaluate the sensitivity of the test in assessing subtle changes in disease course, a potential pitfall of the ubiquitously used 6MWT.

Participant Eligibility

Patients diagnosed with Pulmonary Arterial Hypertension (PAH) World Health Association (WHO) Group 1 and Pulmonary Venous Hypertension (PVH) WHO Group 2 disease on differing pharmacotherapies and are within 18 to 80 years of age.

Control subjects will be healthy, age matched volunteers.